new dog towniniti neutral tp
price month
 close
neutral follow out-performance fourth-largest anim health
therapeut compani elanco anim health highli lever
robust industri fundament across livestock companion anim
market earn growth acceler dedic innov
effort dramat improv cost structur nimbl
unencumb entiti unchain larg pharmaceut parent
focu effici initi drive bp oper
margin expans meaning feat support double-
digit ep growth next five year
innov effort target faster-grow higher-margin segment
diversifi portfolio product line speci therapeut class
contribut consist top-line growth par industri
longer term estim product launch next five
year add million annual revenu execut
oper effici initi underway target bp oper
market expans bp build free cash flow
support de-lever near term dividend tuck-in
share sinc ipo sept believ
valuat adequ reflect advantag leader anim health
sector inher shelter payor reimburs risk
regulatori challeng develop
human
counterpart tp base ev/ebitda
premium competitor zoeti anim health peer group
consider innov profit ramp expect risk epidemiolog
weather regulatori competit fx dynam stake may
serv overhang
warrant ahead
ineffici
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
fourth largest anim health pharmaceut compani
focus develop therapeut supplement
livestock companion anim diversifi portfolio includ
brand market countri
blue sky scenario assum greater expect
adopt product launch expedit pipelin success
meaning profit ramp on-going oper effici
initi specif increment million
annual sale product launch increment bp
oper profit margin expans would drive upsid
current ep estim support blue sky scenario
grey sky scenario assum draconian
fundament backdrop companion product anim health
fundament greater competit headwind new exist
product line lower expect ramp profit
separ parent specif flat top-line growth
bp ramp profit would translat ep
growth contribut grey sky scenario
 close
tabl content
favor product anim dynam sale
expand exposur robust companion anim market sale
earn outlook financi resourc
figur diminish exposur challeng
challeng mix includ medic import antibiot tylan pulmotil well
ractopamin product optaflexx paylean
later
sale growth sale million quarterli revenu newproductsyoy growth new total revenuesal millionsrevenu challeng mix total revenu challeng animalfood animaltot charl martineau univers toronto
initi coverag neutral rate
target price fourth-largest anim health compani global focus
develop manufactur medicin vaccin livestock core
revenu companion anim gener estim billion annual
revenu form eli lilli plant anim scienc
divis becom dedic anim health product septemb
spun interest initi public offer million primari share
unencumb stand-alone entiti free rein expect
benefit enhanc strateg oper flexibl invest capit
deploy opportun offer upsid
global anim health industri worth estim billion includ billion
associ medicin vaccin grow mid-singl digit annual volum
price innovation/lin extens stem sale product
servic promot health welfar livestock cattl poultri swine sheep
fish companion anim dog cat hors given strong
fundament broadli view anim health sector attract space health
care evad much associ risk human counterpart also inher
advantag effici oper sustain product portfolio limit
gener threat meaning direct exposur payor reimburs cut
detail initi public offer
perform sinc ipo
innov effort
busi mix histor skew toward slower-growth
acquisit materi enhanc diversifi portfolio notabl acquisit
novarti anim health boehring ingelheim vaccin portfolio
strengthen exposur companion anim market inher faster-grow
speci group commit bolster companion anim portfolio among
faster-grow segment expect becom increasingli greater
compon mix contribut consist top-line growth line
industri leader anim health highli lever robust
industri fundament aforement inher competit advantag
advantag mind amid healthi fundament demand backdrop across
companion product anim market believ acceler ep growth
strategi
new product innov continu build product pipelin nine
meaning product launch sinc on-going program
potenti novel shot goal next five year across multipl speci group
indic formul target new chemic entiti novel combin
product signific line extens across faster-grow higher-margin segment
brand life-cycle manag effort also enabl sustain build share
among exist product line enter new market ad speci indic
creat new formul support robust pipelin estim
launch signific product next five year add million
annual sale estim new product launch
cours gener million annual revenu
meaning oper margin leverag free parent eli lilli rein
independ entiti optim stand-alone oper
associ profit margin improv drive acceler earn growth
next five year specif on-going cost structur initi drive basi
point oper margin expans dilig focu state
initi includ ration manufactur footprint elimin cmo
two site strateg insourc suppli chain oper sku ration
improv procur term optim salesforc strateg distribut
relationship effort drive increment million annual cost
save execut way initi
capit deploy opportun build earn growth momentum
expect cash reserv expand capit deploy strategi
focu de-lever dividend initi follow share repurchas
longer term target gross leverag ratio point
may activ pursu potenti a/partnership would help fortifi
product portfolio develop pipelin offer upsid estim
valuat reflect invest strength risk share vs
sinc septemb ipo believ valuat adequ reflect
advantag leader anim health inher shelter payor
reimburs risk regulatori challeng develop ineffici human
counterpart contribut neutral rate target price base
ev/ebitda multipl premium competitor zoeti outperform
anim health peer group believ modest premium zoeti warrant
ahead build innov contribut notabl profit ramp expect
risk includ epidemiolog weather regulatori competit fx dynam
interest may also serv overhang
segment core sale primari speciestarget compound-annual-growth-rate market cagrtarget platformscompanion anim diseas prevent vaccinescompanion anim anim futur protein health nutrit health pharmaceuticalsfood anim rumin swine cattl dairi cow charl martineau univers toronto
focus
fourth-largest anim health compani global gener billion
develop manufactur commerci
therapeut vaccin parasiciticid medicin feed addit livestock
core sale companion anim elanco form plant
anim scienc divis becom sole dedic anim health product
septemb spun interest initi public offer
million primari share follow footstep zoeti spin-off
anim segment nimbl stand-alone anim health
compani divers portfolio brand support health well-b
companion pet promot safe effici anim protein product across
countri
independ entiti expect benefit enhanc strateg
oper flexibl invest capit deploy opportun
figur anim health industri leader revenu billion
production/food anim revenu
food anim futur protein revenu compound-annual-growth-rate
segment includ vaccin nutrit enzym animal-onli antibiot
primarili poultri aquacultur fish focu vaccin altern
antibiot import human medicin enzym market
leader prebiot probiot
food anim rumin swine revenu compound-annual-growth-rate
segment compris product cattl swine sheep goat aid
livestock produc improv health safeti effici protein
product also includ elan largest-sel product rumensin
account revenu
companion anim revenu
companion anim diseas prevent revenu
compound-annual-growth-rate segment includ parasiticid vaccin prevent
diseas companion anim dog cat hors comprehens
parasiticid portfolio help protect pet contract vector-born diseas
associ broad spectrum parasit flea tick heartworm
roundworm hookworm whipworm tapeworm among other
companion anim therapeut revenu compound-annual-growth-rate
segment includ product treat chronic diseas pet focu pain
osteoarthr gallipr otiti cardiovascular dermatolog condit
coincid spin also identifi certain busi unit plan
divest/deemphas strateg exit revenu includ fort dodg iowa
contract manufactur organ acquir previou acquisit
distribut agreement adequan equin degen joint diseas treatment
ethicon line surgic suppli companion anim imaverol equin product
japanes pet care busi plan add addit busi unit
product line segment expect dispos busi
reflect model
compani data credit suiss estim estim revenu strateg exit
eli lilli enter anim health space launch first antibiot
exclus veterinari use compani ad new plant anim scienc
activ agricultur industri sale divis conjunct
reorgan agricultur industri sale divis eli lilli form elanco
product compani maintain focu plant anim health scienc
elanco advanc livestock health product halt plant
scienc focu rebrand
enter meaning companion anim arena via launch
comforti oral flea tick treatment medic dog cat comforti
launch broadli view success captur double-digit market share within
month launch elanco continu captur market share gain
sinc elanco evolv top-four player anim health via continu
innov multipl acquisit
busi mix histor skew toward livestock product recent
transform acquisit dramat enhanc diversifi portfolio
includ novarti anim health boehring ingelheim vaccin portfolio last
year commit strengthen companion anim portfolio among
faster-grow segment expect becom
compon mix illustr figur
figur speci mix trendsexpand exposur faster-grow
specif acquir novartiss anim health unit billion sale
notabl boost exposur faster-grow companion anim busi
revenu vs previous novarti anim health asset includ
companion anim product interceptor heartworm food anim product denagard
antibiot swine poultri
decemb anim health-ded investor present eli lilli
announc object improv elanco oper margin
rang food anim sale headwind novarti integr
competit dynam companion anim parasiticid stunt effort
underscor manag consist focu enhanc profit prior
novarti anim health acquisit elanco improv oper margin
januari elanco acquir boehring ingelheim bi us felin canin
rabi vaccin portfolio million includ eight product line along
iowa-bas manufactur facil notabl portfolio ad million
annual sale plan leverag global reach expand portfolio
intern acquisit vaccin portfolio along previou acquisit
novarti anim significantli reduc elanco exposur commodit
lower-margin busi
demonstr focu faster-grow speci product segment note
aforement bivi vaccin portfolio previous part legaci wyeth fort dodg
anim busi sold boehring ingelheim satisfi anti-trust
matter part pfizer/wyeth merger
octob parent eli lilli announc initi strateg review elanco
decis move forward ipo later announc juli
stock price septemb initi public offer exchang cede
compani control asset includ spin-out eli lilli
receiv billion elanco billion debt borrow elanco billion
proce gener elanco ipo experienc zoeti spin
may offer stake sharehold though requir
six-month lock-up period prevent march
figur histor timelin recent transform diversifi portfolio
elanco geograph divers busi lead presenc across four
geograph segment extens global footprint sale repres
across countri outsid us second largest market brazil
credelio februari chewabl tablet prevent treat flea/tick million acquisit boehring ingelheim us felin canin rabi vaccin includ duramun canin infecti diseas vaccin million petx outperform exclus global right develop manufactur commerci gallipr abil co-promot product gallipr post estim million sale potenti grow novarti anim companion livestock aquacultur sale novarti product capstar treat live flea interceptor heartworm denagard antibiot swine lohmann anim poultri vaccin million portfolio includ avipro vaccin protect poultri varieti diseas includ acquir chemgen million ad feed enzym product food anim futur protein launch trifexi chewabl tablet kill flea prevent flea infest prevent heartworm diseas control gastrointestin worm trifexi current elanco product estim million expand intern europ acquisit janssen anim focus swine poultri ad market launch comforti chewabl tablet kill flea prevent flea infest dog jumpstart effort companion anim parasiticid acquir ivi anim add implant begin shift agricultur focu anim lilli set agricultur industri sale lilli introduc one first antibiot exclus veterinari charl martineau univers toronto figur geograph mix speci figur geograph mix core revenue
compani data credit suiss estim revenu strateg exit exclud
revenu
compani data credit suiss estim figur chart approxim
grew compound-annual-growth-rate billion buoy
meaning launch companion anim busi acquisit
novarti anim health lohmann anim health chemgen janssen anim health
note trifexi oral heartworm/flea product achiev consider share gain
follow launch gener estim million revenu
elan top-fiv gross product rumensin trifexi maxiban denagard
tylan premix revenu aggreg repres rel divers product
mix overli skew toward one product line
launch rumensin brand name monensin feed addit use
improv effici prevent coccidiosi beef cattl dairi cow goat calv
improv digest rumensin help anim gain weight quickli dairi cow
rumensin drive increas milk product yield rumensin fulli approv fda
animal-onli antibiot make less suscept regulatori pressur
gener million revenu compani expect rumensin reach
peak sale like face competit
trifexi oral heartworm/flea parasiticid dog sale trifexi acceler
novarti anim health halt product compet product interceptor sentinel
follow manufactur facil shutdown relat safeti issu associ
human drug still promin brand sale trifexi declin
competit new chewabl flea/tick product nexgard bravecto
simparica emerg gener million revenu plan off-set
trifexiss share loss gain recent launch credelio interceptor
discuss figur
top product detail
companion anim north anim north north charl martineau univers toronto figur elan product
fourth-largest anim health compani market share top
four compani control market anim health sector still highli
competit sever global albeit less diversifi compani expand product
line capabl alongsid enhanc market effort term opportun
market share gain focus gain share faster-grow categori
includ companion anim prevent food anim futur
product salesspeciesmod administrationtherapeut dairi cow goatsin feedfe effici control coccidiosi increas milk product dairi cowslaunch top sell product compani sale year expect achiev peak sale heartwormlaunch sell product million sale million due competit nexgard bravecto simparica sale move on-line feedcoccidiosison top five sell product animal-onli antibiot ionophor prevent coccidiosi feedbacteriaon top five sell product anti-infect use treat control bacteria shared-class antibiot acquir novarti anim swine poultryin feedlawsonia intracellulari intestin diseas one top five sell product shared-class antibiot part challeng mix face signific headwind along ractopamin product pulmotil expect gener estimate million sale combin pulmotil estimate million ticklaunch blockbust potenti potenti million annual sale administ dog puppi weigh lb older week old interceptor plusdogsoralheartwormlaunch reformul interceptor acquir novarti anim health compet heartgard market share petx revenu share first calendar year launch purchas clinic ytd million sale ltm osurniadogsliquid dropsextern ear infectionslaunch gel formul appli like liquid stay ear like gel origin legaci novarti anim health pipelin clynavsalmonvaccinepancreat diseaselaunch reduc mortal caus pancreat diseas highli contagi diseas preval chile norway imvixasalmonin feedsea liceprev control sea lice farm salmon one-third fish life preval chile norway achiev market share chile intepritypoultryin feednecrot enter intestin diseas animal-onli antibiot prevent mortal chicken one newli launch product kavaultswinein feed colireduc incid sever diahrea presenc coli newli wean pig one newli launch vaccin acquir boehring million sale variou product protect virus includ distemp adenoviru parvoviru parainfluenza diseas bronchishielddogsvaccinevariousprotect bordetella virus part portfolio acquir boehring dogsoralheartwormacquir novarti anim health launch dogsoralflealaunch administ dog cat week older elanco first signific companion anim launch onsiorcat dogsoralpostop pain inflammationcontrol post-operative pain inflamm follow variou procedur acquir novarti anim health presenc countri atopicadogsoralatop dermatitiscontrol atop dermat dog weigh least four lb acquir novarti anim health avipropoultryvaccinesalmonella newcastl diseas variou diseasesacquir lohmann anim health feedfe efficiencyacquir chemgen improv weight gain feed convers feedgrowth promotionractopamin product beta adrenoreceptor agonist increas weight gain improv feed effici increas carcass lean forecast sale million combin paylean compound-annual-growth-rate due brand gener competit feedgrowth promotionractopamin product beta adrenoreceptor agonist increas weight gain improv feed effici increas carcass lean forecast sale million combin swinein feedrespiratori diseaseshared-class antibiot part challeng mix face signific headwind along ractopamin product tylan expect gener estimate million sale combin tylan estimate million charl martineau univers toronto
figur anim health competit landscap revenu
compani data credit suiss estim calcul assumpt billion market size billion
zoeti largest anim health compani zoeti outperform billion
revenu hold market share diversifi anim health compani
term speci geographi therapeut class like zoeti
by-product spin-out larg human pharmaceut compani
base revenu speci zoetiss busi compris livestock
companion anim dog cat largest speci segment
follow cattl swine poultri geographi zoeti split
evenli mix us ou maintain strong intern
presenc key emerg market includ brazil compani revenu
china well develop western european market australia
compani data credit suiss estim figur base financi exclud strateg exit
recent year zoeti built atop dermat portfolio companion anim
apoquel cytopoint expect achiev million
combin sale therapeut categori suspect eye well
zoeti also new chewabl flea/tick parasiticid simparica launch us
also player recent launch credelio januari
simparica despit label defici expect reach blockbust statu
million gener
may zoeti expand presenc anim health diagnost via billion
purchas abaxi acquisit enabl zoeti leverag global sale footprint
market abaxiss diagnost product intern zoeti view increment
opportun livestock diagnost longer term tabl
expect meaning enter diagnost market near term
revenu boehring
second-largest anim health compani subsidiari boehring ingelheim bi
subsidiari repres total bi revenu importantli januari
boehring ingelheim complet exchang consum health care busi
sanofi legaci merial anim health busi coincid asset swap
ftc requir bivi divest us anim health vaccin asset elanco
acquir million januari
prior acquisit merial bivi mix heavili skew toward livestock
repres anim health revenu top livestock product ingelvac
circoflex vaccin immun swine porcin circoviru type post
revenu million
headquartersgreenfield inparsippani njpharma parent pre-spin year million ou sale geographybrazilbrazilcountri product anim sale sale productrumensin million feed supplement cattl dairi cow improv product effici control coccidiosisceftiofur million inject antibiot treat multipl diseas cattl sheep swinetop companion anim producttrifexi million apoquel million parasiticid portfoliocredelio flea/tick interceptor heartworm/tapeworm/roundworm/hookworm trifexi flea/heartworm/roundworm/hookworm comforti flea capstar flea over-the-count parastar flea/tick over-the-count cheristin cat flea over-the-count simparica flea/tick proheart heartworm/hookworm revolut dog flea/heartworm/ear mites/american dog tick stronghold cat flea/heartworm/roundworm/hookworm atop dermat portfolioatopicaapoquel cytopointgross ebit margin spend on-going sale peoplesal forc peoplenatur entangl time spin manufactur product manufactur one product humatrop manufactur multipl product two compani share certain manufactur site access pharma parent compound librari post-spintwo year plu three one-year option discretionseven charl martineau univers toronto
gain merial provid boehring power companion anim asset boost
posit second-largest anim health compani legaci merial
top product includ nexgard chewabl flea/tick line dog million
sale frontlin topic flea/tick line dog cat million
sale heartgard top-sel deworm dog million
merck anim health merck anim health busi billion
revenu third-largest anim health compani repres parent
merck revenu also known intervet boast divers rang product
speci geographi therapeut class speci includ cattl swine poultri
aquacultur companion anim offic countri product
avail countri
rel peer merck anim health hold outsiz intern focu
revenu earn outsid us like elanco merck strong ou
livestock busi gener unit revenu merck
anim revenu gener companion anim busi
flagship bravecto flea/tick parasiticid launch key driver
note follow announc elanco ipo merck manag reiter
commit expect retain anim health busi togeth human
health busi believ anim health busi benefit chain
human pharmaceut parent integr protein vaccin technolog share
across portfolio howev would note inher advantag
stand-alone concept well merck also believ anim health add divers
busi mix via differ risk profil rel human pharmaceut thu
retain may help less meaning driver human segment
note merck highlight opportun innov oncolog diabet
bayer anim health bayer anim health unit gener billion
revenu repres parent bayer revenu unlik larger
peer bayer anim health skew companion anim repres
revenu anim health revenu key product includ advantag
flea/tick topic line dog cat nearli third revenu seresto flea/tick
collar dog cat drontal deworm baytril antimicrobi product
companion product anim livestock addit baytril bayer offer
cydectin liquid pour-on cattl use remov horn fli lice mite worm
acquir boehring bayer mix significantli skew toward select top
product advantag seresto drontal baytril repres total
anim health sale
sant animal base netherland sixth-largest anim
health compani billion revenu uniqu stand-alone anim
health compani mix predominantli weight toward livestock
repres approxim revenu signific presenc poultri
second largest supplier poultri vaccin market share
largest hatcheri vaccin vaccin in-ovo day-old chick
launch cevac ibra vaccin poultri target bronchiti also increas
rumin presenc acquir inova brazilian foot-and-mouth diseas
specialist geograph largest presenc europ follow mena
smaller presenc north america also notabl presenc
latin america asia
virbac virbac ticker virp-fr post billion revenu
companion anim product anim largest product
categori companion parasiticid repres sale includ
sentinel legaci novarti anim health heartworm product acquir
million regulator-mand divestitur pursuant acquisit
novarti anim health also meaning bovin presenc cattl
antibiot parasiticid repres sale respect
rumin product repres revenu geograph perspect
virbac market share north america europ apac/south africa
latin america
phibro anim health phibro neutral publicli trade compani
anim health nutrit chemic busi post million calendar
revenu million gener anim health busi
anim health busi date sole focus livestock market
significantli skew toward medicin feed addit grow
exposur vaccin nutrit specialti categori interestingli earli
stage develop canin lyme diseas product repres first foray
companion anim
key product virginiamycin market stafac eskalin v-max depend
speci countri market year use
prevent necrot enter poultri virginiamycin also use treat control
swine dysenteri help protect cattl liver abscess also sell varieti
anticoccidi
dechra pharmaceut base unit kingdom dechra dph-gb
post million revenu term speci vast major
revenu gener companion anim product includ
pharmaceut nutrit product geograph dechra weight
toward europ sale north america far east
repres revenu dechra acquir putney us
develop gener companion anim pharmaceut million newer
focu gener differenti dechra major larg player reli
novel therapeut innov line extens
vetoquinol base franc global revenu million
vetoquinol veto-fr largest anim health player vetoquinol revenu
split rel evenli speci approxim sale associ
livestock companion anim like mani peer vetoquinol
work reduc antibiot exposur repres revenu
geograph approxim revenu gener
europ north america asia-pacif vetoquinol increas
invest seek spread risk via partnership livestock
infect
osteoarthr
dermatolog parasiticid
mastiti respiratori
mix base core revenu
given strong fundament believ anim health sector attract space
health care evad much associ risk human counterpart
inher advantag effici oper sustain product
payor
reimburs cut reimburs risk
threat meaning direct exposur
favor product anim dynam sale
product anim market expect grow compound-annual-growth-rate
base data vetnosi demand anim protein rise fuel global
popul growth associ rise demand safer effici sourc
protein one three peopl need improv nutrit world-wide accord
food agricultur organ fao unit nation product poultri
swine speci group project grow cagr
respect dairi beef cattl grow cagr
respect therapeut class accord vetnosi medicin feed addit
project grow compound-annual-growth-rate focu shift toward nutrit specialti
altern antibiot medic import human medicin
driver includ need greater product increasingli scarc natur
resourc rise urban heighten focu consum regul
disease-fre safer sourc protein current global valu agricultur
output stem livestock sector arabl land dedic produc
feed livestock product
billion cash receipt cattl product largest agricultur commod
us accord usda term valu annual product cattle/calf
product dairi product repres two top four agricultur commod
us underscor import divers speci exposur broiler
poultri rank fifth billion cash receipt
animalsprotein productionbeef charl martineau univers toronto
figur global popul expect grow
escal need feed world
growth emerg market exceed experi larger develop
economi necessari modern product anim infrastructur
improv product anim health protocol improv yield advanc
diagnost genom diagnost prevent practic area
potenti focu solut emerg evolv improv livestock product
outsid convent therapeut
figur product anim dynamicsdiversifi driver across geographi less tie broader
follow year contract us cattl herd size expand recent year
accord usda improv forag condit lower input cost primarili
corn-bas feed tie eas pressur livestock produc
term product anim speci us swine poultri product grown
faster beef recent year report usda feder
inspect annual beef product growth us rel flat annual pork
poultri product increas respect higher growth pork
poultri driven lower product price rel beef
asia pacif revenu global popul expect increas two billion asia avian influenza outbreak hinder poultri growth china rapidli grow demand meat philippin vietnam increas affluenc drive demand qualiti protein increas modern anim product ie movingproduct larger unit previous unreach smaller famili farm chines pig popul current latin revenu rise demand protein higher incom popul fastest region increas per capita meat consumpt expect next year increas modern anim product harmon regulatori standard grow activ world trade requir sophist veterinari care drive export market high export anim protein europe/africa/middl east revenu eastern europ middl east africa rapidli grow livestock market emerg middl class increas focu self-suffici drive livestock export russian saudi arabia introduc polici self-sufficiencywestern europ strict regulatori environ increas use meat product process product challeng macro environ diminish industrialcompetit howev largest anim health market render somewhat resili macro issu north revenu activ livestock regulatori environ increas global demand drive export demand trend rel stabl recess shift beef/pork poultri higher intens medic care modern product practic strong macroeconomi nafta import trade flow us/canada maintain activ cattl flow base feed charl martineau univers toronto figur favor livestock dynamicsusda
cattl inventori project head
figur usda histor monthli cattl feed
global meat export expect rise specif
rise demand driven faster growth stem emerg market outpac global
product expect drive growth meat import asia mena us
brazil reap meaning benefit lead export
figur global product beef pork chicken
figur global export beef pork chicken
usda mt megaton cwe carcass weight equival rtc readi cook
moreov oecd agricultur organ unit nation project million
ton addit meat produc global increas key speci
group addit meat produc deriv product
develop countri develop countri importantli estim
revenu tie emerg market nearli half addit meat
expect sourc poultri focu area term innov
swine beef forecast account increas rise
global incom acceler growth demand beef consum expand
diversifi consumpt second- third-lead player global poultri
head cattl feed changemillion mt cwe rtc beef export chgpoultri export chgpork export chgbeef exportspork exportspoultri charl martineau univers toronto
cattl respect well pois benefit macroeconom tailwind
come decad
figur meat product growth countri million ton
addit meat produc driver develop market
oecd-food agricultur organ unit nation outlook
address global trade dynam natur hedg place
oecd analysi assum minim impact unexpect chang intern
trade polici howev us trade agreement garner increas scrutini late
global landscap potenti fundament chang event deal
termin restructur
note august us mexico agre revis nafta canada join
agreement septemb new deal known us-mexico-canada
agreement usmca though note deal pend us congression approv
accord wall street journal part usmca canada grant us
abil suppli dairi market greater agre
trans-pacif partnership us withdrew although higher-quota
threshold repres modest posit us dairi produc anim health
supplier substanti benefit compani come
remov overhang uncertainti usmca year durat
broadli rel diversifi anim health compani geographi
abl leverag sizabl global footprint inher offset market
major fluctuat trade agreement assum dynam meaning
influenc consumpt overal demand protein global
diminish exposur challeng categories/antibiot
anim produc use antibiot herd flock treat prevent manag
diseas well enhanc anim product accord oecd antibiot
improv product product gain larger emerg market
altern freeli avail robust prevent measur
howev recent controversi revolv around concern relat inappropri
use medic import antibiot mia treat bacteria virus
microorgan anim occur human well studi shown
antibiot use food anim could correl human resist mia
ton charl martineau univers toronto
pursuant fda veterinari feed direct vfd rule announc decemb
enact januari mia administ use feed water
us requir veterinari prescript vfd also includ voluntari ban guidanc
industry-gfi agre manufactur requir label state
medic use growth promot purpos prophylact use
countri similarli enact restrict outright ban mia eu
ban market mia growth promot
regulatori pressur relat mia hurt livestock sale anim health
pharmaceut manufactur shown figur zoeti exampl
report vfd-relat pressur reduc sale million
regulatori consumer-driven pressur remain antibiot still import
livestock health treatment purpos survey product anim
veterinarian food highlight veterinarian food
produc food product stakehold believ rais anim without
antibiot like lead depress product effici higher rate morbid
mortal similarli american veterinari medic associ chief economist
dr matthew saloi told new york academi scienc broiler rais without
antibiot averag mortal rate higher
shown figur anim health pharmaceut manufactur shown
recent sign improv livestock sale sale rebas follow
widespread vfd implement trend posit stakehold sentiment
help inform view absent innov antibiotics-rel sale declin
compani data credit suiss estim includ result food anim futur protein food anim rumin
swine segment figur repres calendar year perform
importantli sinc significantli reduc exposur refer
challeng product line includ two feed-grad antibiot tylan
pulmotil well two ractopamine-bas product optaflexx cattl paylean
swine also face regulatori scrutini countri china describ
greater detail page ractopamin growth-enhanc supplement
face pressur gener competit foreign market restrict tylan
remain one elanco five highest gross product sale challeng portfolio
repres total sale
rel flat growth date lap vfd headwind mia account
revenu compound-annual-growth-rate exclud fx
gener intern market north america within residu
exposur overal revenu tylan treatment intestin
diseas swine cattl poultri pulmotil treatment respiratori diseas
cow pig broadli sale challeng product
disproport higher mani industri constitu exposur shrink
impact antibiot rais without antibiot product anim welfar report anim ag allianc
avma economist provid insight antibiot sustain http //www avma org/news/pressroom/pages/avma-
compani us food charl martineau univers toronto
meaning repres estim revenu increasingli focus
innov exist faster-grow product line
figur declin exposur challeng mix
challeng mix includ medic import antibiot tylan pulmotil well ractopamin product optaflexx paylean
expand exposur robust companion anim market
global companion anim therapeut market worth billion grow high
singl digit rise pet ownership increas spend per anim across
develop emerg market inher faster-grow higher-margin
categori continu increas exposur speci group support
current state companion anim health industri given econom malais
veterinari util trend us weaker sharp declin
veterinari clinic traffic weaken new pet ownership trend lower patient
adher total veterinari offic visit declin heel estim
declin accord american veterinari medic associ avma
patient visits/week drop patient averag histor current
accord latest survey yoy howev declin trend began
abat veterinari clinic traffic rebound figur
frame refer prior econom downturn annual practic revenu
histor increas annual averag treatment fee increas
exceed howev lower patient volum disproportion weigh
practic revenu challeng econom backdrop current
approach higher level late hearten recent survey work
suggest continu strength veterinari demand despit difficult yoy comparison
ncevi updat veterinari demograph econom trend may
total revenuesal millionsrevenu challeng mix total revenu challeng charl martineau univers toronto
figur companion anim demand remain strong
lacklust routin veterinari visit industri largest battl
reflect declin quarterli same-stor volum vca lead stand-alone
anim hospit chain hospit howev vca report first posit
same-stor hospit sale trend consecut quarter signal inflect point
veterinari demand overal expect sustain momentum veterinari clinic volum
practic revenu help prolifer advanc diagnost test
pet ownership innov clinic technolog sophist therapeut
figur total us pet industri expenditur billion
appa credit suiss estim note expenditur includ food supplies/otc medic vet care live anim purchas
groom board
store salesidexx-measur practic visitsidexx practicerevenuesidexx practic volumenot includesan extra sell daywoof charl martineau univers toronto figur us pet expenditur breakdown
highlight relev metric track well proprietari survey work suggest
rise pet ownership accord american pet product associ appa
annual survey us pet ownership level reach high us household
own pet term speci million household million dog
million household million cat rise pet ownership driven pet industri
expenditur steadili higher grow compound-annual-growth-rate sinc reach estim
billion addit pet medic purchas complet
veterinarian underscor import pharmaceut compani maintain
strong relationship veterinarian
figur number us household own pet million
vet anim servic groom petsmart petco fishsaltwat fishreptilebirdsmal animalin us household charl martineau univers toronto
figur estim pet ownership rate countri speci
pet adopt veterinari prescript trend indic overal pet demand
baromet perform compani signific exposur companion
anim market gener core revenu companion anim
segment accord pethealth inc lead provid manag softwar
anim welfar organ north america year-over-year growth pet adopt
across anim shelter rose august averag growth
adopt led gain improv year year canin adopt improv
note averag price canin veterinari visit higher felin
visit accord adopt anim shelter repres new pet
acquisit us pet euthanasia invers correl pet demand drop
august consist recent monthli trend posit overal pet ownership
rise spend per pet momentum companion anim veterinari
demand continu younger gener becom increasingli will
spend pet figur importantli us veterinari spend also shown
rel resili even recessionari period
figur millenni will spend
figur recessionari resili total us
us bureau econom credit suiss estim
accord iqvia monthli adjust total script prescrib veterinarian increas
august acceler rise juli importantli metric continu
track well ahead human prescript note veterinari medic
dispens veterinari practic fulli captur data
note iqvia exclud veterinary-exclus therapeut flea/tick medic thu data may fulli reflect fluctuat demand particularli higher-volum
flea/tick season result reflect restat juli reflect chang vendor coverag iqvia may slightli estim inflat veterinari prescript trend
proprietari survey work point broader optim veterinari demand
base survey us veterinari practic see note titl survey say
vet demand bite experienc posit patient traffic experienc increas
practic revenu weighted-averag basi volum rose practic
revenu similarli improv primarili driven new patient traffic acut
care visit diagnost price discretionari procedur
credit suiss quarter shown
credit suiss quarter shown
importantli new patient traffic meaning driver patient visit key
indic pet ownership trend underli veterinari demand delay onset
flea tick season posit impact veterinarian note earlier
flea tick season note harsher flea tick season rel
note iqvia exclud veterinary-exclus therapeut flea/tick medic thu data may fulli reflect fluctuat demand particularli higher-volum
flea/tick season result reflect restat juli reflect chang vendor coverag iqvia may slightli estim inflat veterinari prescript trend
sentiment respond optimist next month well
veterinarian expect stronger result patient traffic come month vs
weighted-averag basi respond
expect patient visit rise next month compar
respond experienc practic visit respond experienc practic revenu patient trafficwel visitsdiscretionari procedur volumesdiagnost test volumespricingacut care visitsnew patient charl martineau univers toronto
veterinarian survey expect
declin patient visit veterinarian also remain optimist regard practic revenu
expect weighted-averag increas next month consist
recent survey cohort report expect
major respond broadli expect strengthen overal demand consist
view favor veterinari condit
credit suiss quarter shown
credit suiss quarter shown
continu build product pipelin nine meaning product launch
sinc on-going program potenti novel shot goal
next five year across multipl speci group indic formul
target new chemic entiti novel combin product signific line extens
across faster-grow higher-margin segment typic anim health compani
brand life-cycle manag effort also enabl sustain build share
among exist product line enter new market ad speci indic
creat new formul support robust pipelin estim
launch signific product next five year add million
annual sale estim new product launch
gener million annual revenu
figur pipelineampl shot goal
launch nine notabl product across four core segment
imrestor rel young portfolio new product rapidli gain momentum
ormor respond optimist ormor respond optimist vs annual sale contributionest new product launchesrevenu charl martineau univers toronto
gener million revenu million bp bp
top-lin growth respect gener million sale new
product estim contribut bp top-lin growth
figur contribut recent launch product ramp
veterinarian notori slow adopt new technolog underscor elan
potenti long runway sustain growth across new product line
earn confer call zoeti attribut simparica ytd growth part
direct-to-consum advertis campaign stand-alone compani unchain
larg pharmaceut parent prioriti potenti conflict interest
similarli abl improv market effort build greater momentum
view without fight resourc intern
figur revenu contribut product launch expect new
compani data credit suiss estim includ expect contribut product launch beyond
sale growth sale million quarterli revenu new productsyoy growth new charl martineau univers toronto
credelioramp flea/tick portfolio blockbust categori compel
potenti extens launch januari credelio monthli
chewabl tablet prevent flea tick infest dog includ common us
tick lone star tick american dog tick black-leg tick brown dog tick
importantli credelio enter highli covet yet competit chewabl
flea/tick parasiticid arena billion market note accord studi
banfield pet flea infest increas tick
infest declin parasiticid categori one largest
product categori companion anim health
competit posit credelio fourth chewabl flea/tick combin
product market follow boehring ingelheim legaci merial nexgard
merck bravecto zoetiss simparica importantli parasiticid
administ dog age eight week older consist label
nexgard minimum age give credelio advantag zoetiss simparica
six-month age requir accord manag credelio
induc time less gi issues/vomit comparison nexgard estim
price credelio premium simparica discount
nexgard overli aggress price view note see suppli issu
dosag larger dog dynam believ address near term
credelio continu ramp illustr figur figur compar
sale ramp relev compet parasiticid product acceler second
year market also coincid onset flea/tick season
sanofi/meri nexgard launch timelin sale trajectori sale million
credelio sale disclos believ credelio blockbust
potenti million revenu help regain foot us
parasiticid market lag innov standpoint boast
comprehens competit companion anim parasiticid portfolio credelio
trifexi interceptor comforti well over-the-counter product note
veterinarian notori slow adopt demonstr sanofi zoetiss
respect experi nexgard see figur simparica figur
banfield state pet health report http //www banfield com/banfield/media/pdf/downloads/soph/banfield-state-of-pet-
millionsu nexgard salestot nexgard salessep nexgard receiv fda approvaljan nexgard launch usfeb nexgard receiv ema nexgard launch charl martineau univers toronto
figur case studi parasiticid sale zoetiss simparica launch timelin
interceptor plusrebuild endoparasiticid presenc launch octob
us interceptor repres updat formul interceptor
legaci novarti anim health chewabl tablet dog prevent heartworm
intern parasit infect includ roundworm hookworm whipworm
tapeworm make one broadest spectrum endoparasiticid market
along virbac sentinel iverhart product line interceptor one
parasiticid treat tapeworm accord banfield pet hospit tapeworm
seen canin case particularli preval dog less year old
typic southern us
elanco acquir right interceptor formul via billion acquisit
novarti anim health januari novarti voluntarili shut
product companion anim parasiticid portfolio interceptor sentinel
owe suppli issu lincoln nebraska manufactur plant resolv
issu novarti relaunch sentinel discontinu sale interceptor pursuant
acquisit novarti elanco forc ftc divest sentinel
sold virbac million
launch interceptor improv formul expand indic
legaci interceptor product help regain share categori
repres estim share three year post-launch
millionsu simparica salestot simparica salesnov simparica receiv ema approvalfeb simparica receiv fda approvalspr simparica launch us zoeti begin disclos simparica charl martineau univers toronto
galliprantblockbust potenti leverag partnership model like
come launch januari us collabor aratana
therapeut gallipr chewabl tablet prostaglandin receptor
antagonist treatment osteoarthr pain inflamm dog gallipr
part piprant chemic class uniqu block prostaglandin
receptor key receptor involv pain potenti significantli improv
safeti profil current standard care nsaid zoeti rimadyl
gallipr receiv market author europ european medic
agenc approv expect
base quarterli survey us veterinari practic initi feedback gallipr
broadli posit view mani respond safer
efficaci altern rimadyl nsaid particip
report alreadi prescrib gallipr addit consid prescrib
product futur importantli veterinarian current
prescrib gallipr respond highlight prefer gallipr
exist lead treatment rimadyl zoeti suggest build market share
presenc product note typic anticip take least five year
reach peak market share posit new anim health therapeut
prescrib gallipr
plan prescrib gallipr exist
gallipr sale continu rise believ addit
opportun particularli expand european market come year
plan aggress global expans product estim
product potenti achiev million annual sale
aratana therapeut compani data credit suiss estim
figur us oral nsaid market size gallipr
osurnia osurnia specialti canin therapeut treat otiti externa infect
extern ear canal launch elanco acquir osurnia formul
part novarti transact
accord banfield pet hospit dog diagnos extern ear
infect preval golden retriev labrador retriev caus
infect includ food allergi ear mite bacteri infect irrit foreign
bodi ear advantag osurnia includ eas administr appli like
ye alreadi prescrib plan prescrib sure prefer prefer share us oral nsaid market million us market sizegallipr market charl martineau univers toronto
liquid stay ear like gel low-dosag requir two dose
veterinarian admittedli feedback recent survey work
mix osurnia repres share among cohort us veterinarian
note mometamax merck activ prescrib cohort
claro bayer anim health note
clynav launch clynav vaccin protect salmonid
alphaviru sav also known pancreat diseas atlant salmon diseas
preval chile norway export valu salmon trout worth
billion million metric ton salmon produc sav
highli contagi diseas caus inflamm heart skelet structur
lead widespread mortal salmon farm sav like
signific viral diseas sea-farm salmon accord norwegian
veterinari institut new case regist norway
imvixa launch imvixa in-fe therapeut prevent control
sea lice salmon one-third live sea lice preval chile
norway like sav parasit feed fish skin mucu muscl fat make
fish vulner infect occasion kill accord new york
time norway sea lice halv norway wild salmon popul
gentler treatment known resist issu imvixa achiev market
share chile continu captur share norway well
intepr intepr prevent broiler chicken mortal caus necrot enter
intestin diseas estim affect flock cost global poultri
industri billion annual accord estim poultri world
interestingli issu becom preval util antibiot growth
product declin
kavault launch kavault animal-onli antibiot feed addit
reduct diarrhea presenc coli swine age least month
health issu prevent pig gain weight perform product
year launch correlink asia plan launch prevac swine
vaccin experior replac optaflexx cattl ractopamin product
year-end also target addit product launch
disclos natur futur launch plan priorit
inher faster-grow higher-margin categori companion anim
innov focu believ exposur attract speci group
therapeut categori fuel top-line earn growth enhanc visibl
thereon specif estim exposur companion anim segment
expand total sale significantli diversifi
portfolio similarli exposur faster-grow food anim futur protein
segment expand sale
importantli anim health drug develop requir substanti less time
resourc commerci new chemic entiti vs human health care given limit
need complex lengthi human clinic trial consequ likelihood success
determin earlier develop process make effort predict
facilit effici financi decis make new chemic entiti anim health
brought market roughli six year fda regul shorter
usda depend type product half time take commerci
new york time wild salmon declin norway pressur giant fish farm
human drug associ averag cost million compar favor averag
price billion develop major human drug
figur highlight inher effici anim health drug develop vs
consolid footprint site reduc
expens maintain spend level sale
view within industri norm perform biannual portfolio review well
separ gate review prior project invest inflect point ensur
deserv project remain fund control led histor intern rate
return mid-teen
figur mix histor project
histor sourc new product innov rel evenli among access
parent eli lilli human compound intern capabl importantli follow
spin eli lilli provid licens compound librari two year
year pkind filingphas ifield trialsphas iifield trialsanim toxicologyfin formulationhumananim nce nbe proof concept lab animalssar chemistri select leadin vitro toxicologydos selectionprob safeti dogs/catsfin formulationphas human clinic studiesproof concept dog /catsapi formul developmentpk dogs/catsselect leadchemistri optimizationnadaresearch yr approv ii yr approv eu animalfood animaltot charl martineau univers toronto
hold three annual option renew access addit novarti
acquisit provid independ compound librari plan sourc
product innov via intern effort
access compound librari
invest major resourc companion anim diseas
prevent companion anim food anim futur protein
segment companion anim see compel opportun atop dermat
lymphoma kidney diseas well parasiticid product anim
develop vaccin prebiot probiot imper long-term success
compani project long-term studi mix companion/food anim
within companion anim favor product endors veterinari channel
also balanc conveni pet owner
itchi dog specif acknowledg atop dermat
candid jak inhibitor pipelin would potenti compet zoetiss
apoquel cytopoint portfolio howev guid potenti launch time
given apoquel impress sale trajectori million estim million
follow launch launch success believ opportun
could offer upsid estim blockbust categori apoquel cytopoint
consist cite quarterli veterinari survey two impact
recent product veterinari medicin vet note client balk
price suggest market space lower-cost competitor
flea/tick/heartwormth holi grail companion anim health
acknowledg like first market believ elan pipelin also like
would like occur closer view develop
product help off-set futur share loss exist companion anim parasiticid
portfolio competitor like reach market tripl combin
product sooner term player first market note bi/meri
combin product nexgard spectra approv europ one
challeng approv us grow resist protect newer
challeng heartworm strain jyd exist heartworm
parasiticid deriv legaci molecul approv issues/strain
develop new heartworm
combin product view first-mov advantag
billion parasiticid market room multipl player well-posit
abil leverag current portfolio
elanco boast brand date back make one oldest anim
health industri compani deploy salesforc peopl distributor
partner sell brand product licens veterinarian livestock produc
across countri employe countri plan optim
overal sale distribut though direct/distribut mix vari
market us vast major sale distribut compar
germani custom type maintain direct relationship largest client
includ corpor account vca banfield well top food anim
client hope reduc distribut presenc less top
custom mwi veterinari subsidiari one world largest
anim health distribut compani repres compani sale
also work distributor henri schein anim health two larg distributor help
elanco also broken industri norm util on-line retail channel
petm express certain older over-the-count companion anim product
online/retail channel provid new sourc demand gener product like trifexi
flea/heartworm launch comforti launch flea product capstar over-the-counter
brandcompanyvet rxfleatickmosquitoesfliesear miteslicesarcopt mangeheartwormhookwormroundwormwhipwormtapewormmod administrationfrequ dosageminimum ageminimum weight lb isol tick weeks-n/ascalibor protector weeks-n/aheartgard weeks-n/aheartgard weeks-n/aiverhart weeks-n/aproheart months-n/atri-heart charl martineau univers toronto
presenc over-the-counter market differenti industri leader over-the-counter
sale current repres revenu howev illustr figur
capstar among frequent recommend parasiticid us veterinarian
proprietari quarterli survey past month survey respond
note recommend capstar note juli elanco launch capact
gener version capstar store
figur credit suiss proprietari survey us veterinarianswhat parasiticid
flea/tick/heartworm treatment commonli prescribe/recommend
compani data credit suiss estim respond note program six-month flea inject cat
figur credit suiss proprietari survey us veterinariansperc
respond recommend capstar pet owner client
compani data credit suiss estim period shown except
anim health pharmaceut compani priorit loyalti veterinari
channel critic mean secur companion anim product adopt on-line
channel grown recent year albeit somewhat owe grey market supplier
note figur pet medic sold via retail on-line channel
elanco program elanco iverhart virbac advantag bayer tri heart merck vectra credelio elanco comforti elanco sentinel virbac advantag multi bayer seresto bayer capstar elanco frontline/plu merial trifexi elanco interceptor elanco simparica zoeti proheart zoeti bravecto merck revolut zoetis/pf heartgard merial nexgard merial number respond respond recommend capstarhistor charl martineau univers toronto
half on-line market stem parasiticid accord rakuten intellig
on-line sale flea tick product increas
view online/retail strategi prove effect need strike
delic balanc promot sale without alien all-import
veterinari channel veterinarian depend sale pharmaceut driver
practic revenu may inclin promot product feel
manag current dog regularli visit veterinarian elanco
satisfi veterinarian achiev financi success help drive better complianc
veterinari visit view
compet channel howev accord
direct pet owner
sinc cut million manufactur cost consolid facil
reduc sku count elimin contract manufactur organ suppli
network transform cost save initi initi remain on-going
dilig focu oper effici initi detail follow page
gener increment million annual cost save
beyond abl improv technic capabl enhanc
product opportun expand insourc program yield save
drive addit million manufactur save help reach ebit
ebitda margin respect
facil consolid optim reduc manufactur footprint
facil close site sligo ireland sold
dunde uk vacavil california process lower manufactur
headcount importantli facil optim continu
slate close addit two facil cali columbia larchwood
iowa year-end respect goal reduc manufactur
headcount employe
ebitda margin expans charl martineau univers toronto
effici initi taken hold clinton speke larchwood plant
though larchwood
consolid fort dodg plant plan simplifi infrastructur five
addit plant aim achiev anoth million save
annual save
million
sku network ration sku current
elimin sku sinc also reduc count
region network compris organ north
america emea latin america asia-pacif plan
reduc network sku ration also continu
product initi cost-cut program includ commit
tower review procur renegoti
initi facilit margin expans
control tower initi repres decentr program site gener
manag perform cost analys respect staff manag strive
achiev million save program note far
ahead pace
procur renegoti yield save up-front contract termin
penalti mask benefit thu far howev benefit
becom increasingli appar lap termin fee compani believ
procur negoti opportun benefit
insourc invest also way believ
effici manufactur certain enzym input companion anim packag
anim health product becom increasingli consumer-centr term
brand packag increas area focu across segment note
hire employe cpg background acceler associ effort
build earn growth momentum expect cash reserv expand
capit deploy strategi focu de-lever dividend initi
follow share repurchas longer term
conjunct ipo borrow billion paid along
net proce share issuanc equiti stake sold public
investor includ debt load billion senior note matur date
rang coupon rate rang elan gross
leverag net leverag ratio current stand ttm ebitda ttm
ebitda respect initi borrow yield estim run rate
million interest expens annual howev manag target aggress
debt paydown strategi like begin target gross leverag
ebitda year-end fund build strong cash flow oper estimate
million
addit debt paydown manag priorit dividend begin
plan pay million forecast adjust net incom see figur
dividend annual hike thereaft longer term opportunist
acquisit help fortifi product portfolio develop pipelin along
potenti partnership collabor compani state interest
pipelin deal joint ventur research collabor partnership may also
provid access new compound help develop relationship across
institut academia among
convent channel potenti deal size like small near term
million rang potenti larger achiev leverag target
yearcompani ingelheim us vaccin felin canin rabi anim sale global companion anim livestock brand acquir includ interceptor anim vaccin includ avipro poultri guardundisclosedcattl enzym product poultri egg swine anim undisclosedeuropean presenc acquir johnson anim undisclosedlivestock implant data charl martineau univers toronto
earn outlook financi resourc
report basi revenu growth essenti flat admittedli
industri growth face headwind competitor innov gener entrant
regulatori headwind off-set acquisit contribut note decis exclud
certain legaci asset posilac agristat spin co add addit complex
compar histor result provid estim elanco histor organ
growth along forecast organ growth figur
follow januari close novarti anim health acquisit
revenu includ posilac agristat increas growth companion
anim growth food anim howev compar organ basi
companion anim revenu declin food anim deterior driven
part emerg merck bravecto boehring ingelheim merial
nexgard compet flea tick product new competit beta agonist product
line optaflexx paylean revenu fx fluctuat bp
exclud posilac agristat core revenu growth flat
increas companion anim off-set decreas food anim increas
companion anim driven growth interceptor osurnia sale
market access pressur relat beta agonist continu weigh food anim
segment sale exclud fx headwind impact strateg exit
estim core constant currenc sale growth increas
companion anim partial off-set drop food anim
acquisit boehring
elan report revenu declin includ decreas core revenu
vetmedica vaccin portfolio deal close januari ad million
revenu exclud vaccin portfolio companion anim sale declin owe
increas competit across flea tick product notabl trifexi comforti
competitor launch new chewabl product partial off-set increas sale
interceptor gallipr launch meanwhil product anim sale declin
driven continu market access pressur gener competit optaflexx
paylean well antibiot pressur caus veterinari feed direct
exclud impact fx aforement vaccin acquisit
estim organ constant currenc revenu growth decreas
companion anim food anim respect note includ
organ revenu growth impact distributor destock result chang
top-line growth less consist believ diversifi
portfolio expedit innov effort drive consist top-line growth
par industri growth longer term importantli remain focus cost-
cut effort alreadi achiev signific save help drive
ebitda margin improv bp effort expect continu
come sever year
forecast revenu increas billion elanco sale
exclud strateg exit rise reflect momentum across three target
growth segment certain regulatori competit headwind behind
companion anim diseas prevent estim revenu million
ramp traction new product credelio interceptor
also benefit easier comparison owe distributor destock
caus chang distribut arrang companion anim product
companion anim therapeut unit forecast million sale driven
continu momentum gallipr amid strength underli companion anim
demand consist data point track proprietari survey work
food anim futur protein project revenu million
primarili build traction innov aquacultur product imvixa clynav
well strength across latin america apac food anim rumin swine
forecast modest revenu growth billion continu growth
rumensin off-set manag stronger emphasi three primari
segment note food anim top-line growth help go local
initi china shift direct sale model region
result distributor destock
ebitda margin expand bp continu manufactur sg
save initi sku ration procur cost elimin
model assum million interest expens includ pro forma adjust
captur interest expens full year borrow origin august
similarli assum tax rate full year pro forma ep grow
vs pro forma ep
growth rate base financi report compani commentari includ result posilac agristat retained/divest
otherwis includ elanco histor result futur project posilac agristat contribut million combin revenu repres
growth rate includ janssen acquisit close chemgen acquisit close late januari
growth includ roughli one month impact chemgen acquisit
growth adjust lohmann acquisit close april estim lohmann contribut result base commentari
lohmann contribut growth growth lohmann contribut disclos estim averag contribut
arriv contribut lohmann
growth includ lohmann impact includ novarti revenu base year disclos novartiss contribut
growth exclud contribut bivi vaccin portfolio
revenu grow increas across elanco larg off-set
roll-off vast major strateg exit segment assum million
companion anim diseas prevent anticip
endectoparasiticid tripl combin flea/tick/heartworm product launch competitor
potenti bi/meri nexgard tripl zoeti announc august hope
launch simparica trio neg affect sale relev
parasiticid line interceptor credelio trifexi comforti
averag rumensin entrant bp impact million tripl combo entrant bp million new product bp combo parasiticid bp impact million new product bp undisclos acquisit impact janssen food anim vfd gener ractopaminenew product bp companion anim bravectoand nexgard estimate contributionfrom report driven million yoy million yoy bp impact partial off-set pressur food rumensin entrant bp million tripl combo entrant bp million new bp combo parasiticid bp million new product bp million product bp million optaflexx compound-annual-growth-rate charl martineau univers toronto
project ebitda margin expans bp continu cost-sav
initi manufactur along advantag mix divest strateg
exit distribut agreement increas exposur higher margin target growth
categori total revenu given interest expens fall million
result debt paydown tax rate forecast ep increas
long-term basi expect elan top-line growth stabil consist
industri growth focus faster-grow higher-margin product categori
importantli on-going cost structur initi fuel continu oper margin
leverag forecast companion anim revenu grow
compound-annual-growth-rate recent product launch gain momentum support futur
launch potenti high-growth area atop dermat monoclon
antibodi pain also believ elan ebitda margin continu expand
buoy cost-sav initi manufactur
sg well mix continu shift away challeng product line less-
million cash reserv billion debt capit deploy
effort focus de-lever near term estim gener
million million cash flow oper respect
strong cash flow temper estim million non-recurring
standup cost total major incur million
million
cash convers cycl day compar favor though high inventori
balanc day outstand still high high inventori day may
structur natur given exposur livestock industri on-going sku
ration could help address issu specif could see inventori day
declin improv manufactur suppli chain oper technolog
advanc addit smaller manufactur footprint restructur
initi would expect capit expenditur declin benefit free cash flow
told free cash flow forecast ramp significantli million leav
ampl cash de-lever dividend partnership share repurchas
figur convers cycl million
loss eli lilli relationship signific eli lilli ownership benefit
access eli lilli infrastructur compound librari strong reput
broader pharmaceut market variou share function transit
servic agreement place includ access compound librari two year
three addit one-year option eli lilli sole discret start-up cost like
substanti off-set futur cash flow addit approxim share
held eli lilli lock-up period day point share may
experi pressur lilli divest ownership
initi standup cost somewhat disentangl eli lilli around
year headquart mile away offic manufactur
oper almost complet separ manufactur one eli lilli
product humatrop nevertheless incur estim million standup
cost four year develop certain infrastructur back-offic activ
histor receiv eli lilli includ cost new erp system
implement cost expect
past year compris
margin improv effort may fail acquir integr
manufactur site eight site realiz million annual cost save
part integr effort elimin
sku reduc manufactur headcount approxim close three
manufactur site realiz signific save oper margin
remain well industri leader may abl identifi achiev
suffici save compet larg anim health compani
weather related/epidem risk anim health industri exposur diseas
threat drought potenti geograph epidemiolog catastroph
unexpect chang weather pattern diseas outbreak canin flu bird flu
mad cow diseas foot-and-mouth diseas significantli affect posit and/or
neg demand livestock companion anim product
macroeconomic/glob trade risk custom countri
affect macroeconom condit reli variou trade agreement trade
agreement materi alter foreign demand certain anim health product may
suffer may rais price sub-optimal level similarli macroeconom
condit certain countri worsen demand anim health product may decreas
regulatori consumer-driven risk factor antibiot harsher regul relat
rais treatment process consumpt livestock could caus produc
chang treatment paradigm herd flock potenti regul anim
medic dispens surround particular product line medicin feed
addit could neg financi repercuss regulatori risk also encompass
manufactur effort subject oversight enforc pharmaceut
safeti law fda center veterinari medicin respons consum
public health expert advoc judici use antibiot livestock
industri constitu includ reduc purchas meat
anim expos antibiot stop sourc chicken treat
antibiot import human medicin us restaur
ractopamin estim revenu ractopamin beta adrenoreceptor
agonist cattl swine mimic adrenalin typic fed cattl swine gain
averag pound although fda permit use certain intern market
includ china us food produc target export market therefor
less will use ractopamin recent year expect
gener million revenu ractopamin million
industri consolid previou anti-trust matter associ elanco acquisit
boehring ingelheim vetmedica us vaccin pursuant boehring acquisit
merial well elanco divestitur sentinel virbac pursuant acquisit
novarti anim health suggest consolid among industri leader unlik
howev expect smaller industri constitu continu consolid lead
potent competit threat
competitor innov anim health industri intens competit
larger player constantli seek greater innov diversif speci
therapeut class geographi innov area competitor could
hinder elan abil grow
gener competit gener competit rel low anim health industri
owe strong brand loyalti among livestock produc veterinarian howev
veterinari medicin price risen recent year demand gener may
increas time signific portion elan revenu includ top
product rumensin gener product patent protect leav
potenti vulner gener
custom consolid sell anim health product third-parti distributor
veterinarian food anim produc consolid within custom group
could lead reduct elan bargain power hurt abil increas price
result lower profit
 risk intens competit environ depend continu
innov via pipelin mitig risk form extern
partnership broader effort could prove futil lead slower revenu growth
declin revenu
foreign currenc fluctuat inher natur hedg constantli
evolv global anim health market expos currenc fluctuat
sale deriv oversea futur perform like affect
movement euro pound sterl brazilian real australian dollar japanes yen
elanco ipo price per share septemb ep estim
origin suggest rang per share ep estim
midpoint first day trade elan share price spike
close day share price sinc stock price eb vs
 remain ipo price impli market cap billion
vs zoeti billion
exclud ipo price multipl base ebitda estim
exclud ipo price multipl base ep estim
share current trade price-to-earnings ev/ebitda multipl
respect repres premium zoeti broader
anim health peer group posit bias anim health fundament
elan growth prospect believ innov effort profit margin ramp
larg reflect current valuat target price base enterpris
first day sinc price septemb price-to-earnings ebitdacurr ev/ebitda charl martineau univers toronto
valu estim ebitda premium competitor zoeti
anim health peer group believ premium valuat warrant ahead
build innov contribut consider profit ramp expect
addit anim health valuat alreadi notabl high reflect inher
advantag less exposur human health care risk enhanc invest
allur anim health compani histor trade premium broader
 pursuant anim health index see figur view premium
warrant given industri aforement robust fundament backdrop
inher resilient/defens characterist sector vs human counterpart
compani data credit suiss estim anim health index includ abax gen veto virb woof petm mwiv
base analysi strong document correl
valuat cohort anim health compani suggest investor focus
true econom return appli regress enterpris valu invest
capit vs use estim compani indic
variat ev/ic determin compar much weaker correl
convent price-to-earnings multipl ep growth rate well consequ
correl indic market will pay compani gener
higher return invest capit simpli stronger ep growth
forecast calcul divid net oper profit tax averag
invest capit requir earn return larger capit base ad back
reserv doubt account accumul amort after-tax asset relat charg
present valu capit oper leas reserv believ
recent ipo set stage signific improv independ
industri leader focus optim growth profil cost capit structur
base current earn capit spend forecast expect
improv improv profit key driver
possibl upsid stem better-than-expect sale growth innov
better defens potenti headwind includ tripl combin parasiticid
gener rumensin competit entrant overal regress analysi relev
anim health compani roic valuat help support target price
impli valuat slightli higher line best fit
compani data credit suiss estim ev base close price octob per factset
discount cash flow model predic elan profit margin ramp materi
next year project million standup cost disaggreg across
four year associ spin capit expenditur
million million million annual
thereon support valuat stock wacc use reflect
billion outstand debt balanc equiti risk premium target
price support dcf-deriv valuat shown figur better-than-expect
profit margin growth along improv work capit manag higher
dividend pay-out could offer upsid
blue sky scenario assum faster meaning profit contribut
oper effici initi greater-than-expect adopt new futur
product more-muted-than-expect headwind competit launch stronger-
than-anticip growth anim health fundament
grey sky scenario assum lower-than-expect ramp profit
weaker traction new futur product potenti product innov delay
intens competit anticip greater-than-expect cost born
separ eli lilli fx macroeconom headwind weak companion
product anim fundament
elanidxxpahcztshsicpdcor charl martineau univers toronto figur discount analysi million except per share amount
annual futur growthchg work fix invest cash flowpv pv residu debt prefer valu per charl martineau univers toronto
elanco manag team compris veteran relev consum packag
good anim health human health industri importantli sever key
execut extens experi elanco fundament
implement compani growth strategi diversif effort board
director includ five member eli lilli manag includ ceo cfo
chairman board david hoover former ceo
corpor packag aerospac compani control compani eli lilli
own follow ipo elanco requir major
independ director board compens committe corpor govern
namepositionbiographyjeffrey simmonsceoappoint ceo conjunct ipo previous mr simmon serv presid elanco anim health divis join oper varieti sale market manag role elanco includ countri director brazil area director western europ serv board director chiquita swiss produc distributor banana produc luca montarceact cfoact cfo join follow medic leav absenc christoph jensen hire april mr montarc previous fill role latin america europ us experi region cfo role director global treasuri jame meerprincip account officerhir septemb elanco name princip account offic follow ipo previous serv cfo sinc varieti financ account function appirio exacttarget hill-rom prior career industri work ernst young varieti audit work spin-off guidant aaron schachtevp innov regulatori busi developmentmov evp innov regulatori busi develop follow elan ipo prior ipo mr schacht elanco vice-president global research develop sinc join anim health divis oper varieti leadership role human medicin sarena linevp elanco usa global strategyjoin elanco januari svp north american oper strategi preivous work cargil presid feed nutrit global head strategi busi develop also serv director compens audit committe ramiro cabralevp global custom valuenam evp global custom valu conjunct ipo serv chief market offic elanco sinc octob work sinc varieti role within elanco anim health divis carri doctor veterinari medicin nation univers central bueno air purdu univers david urbanekevp manufactur qualityprevi work vice-president manufactur elanco begin novemb join anim health divis mr urbanek fill varieti role includ senior director emerg market manufactur senior director global diabet manufactur kinardevp human resourc corpor affairsfirst join elanco may follow run sever leadership role serv vice-president hr sever busi includ lilli intern bio-medicin emerg market lilli diabet global employe relations/hr oper bryant-hicksevp gener counsel corpor secretaryjoin elanco may evp gener counsel corpor secretari follow stint gener counsel mallinckrodt public liabil compani svp gener counsel corpor secretari provid servic corpor assist gener counsel charl martineau univers toronto
figur quarterli ep million except per share amount
histor resultsproject gener share dilut share analysisnet gener analysisnet gener save gener charl martineau univers toronto
figur quarterli revenu million
histor product categoryca diseas companion futur protein rumin food diseas companion futur protein rumin food growthca diseas companion futur protein rumin food currenc revenu growthca diseas companion futur protein rumin food charl martineau univers toronto
figur annual ep million except per share amount
histor gener share dilut share analysisnet gener analysisnet gener save gener charl martineau univers toronto
figur annual revenu million
histor product categoryca diseas companion futur protein rumin food diseas companion futur protein rumin food diseas companion futur protein rumin food currenc revenu growthca diseas companion futur protein rumin food charl martineau univers toronto
figur balanc sheet million
sheetcash cash expens current non-current equip rebat tax current current retir non-current parent compani paid-in comprehens liabil charl martineau univers toronto
figur histor project flow million
net incom alloc non-controlling amort defer incom compens impair sale non-cash oper ni adjust account account payabl cash provid oper properti plant properti plant sale product paid invest cash provid use invest transact equiti debt financ cash use financ rate effect decreas equival begn equival end flow adj net charl martineau univers toronto
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb
figur elanco segment revenu mix-shift
figur price perform ipo today
thomson reuter compani data credit suiss estim stock price januari ipo occur februari
event/catalystdatepric per share chg prior event zoeti ipo price immedi prior separ plan date separ plan immedi prior date exchang date exchang follow expir exchang end stock price immedi prior spin/ipo immedi follow announc price immedi prior separ plan follow separ plan immedi prior date exchang separ plan announc exchang offer follow expir exchang end price sinc charl martineau univers toronto
compani mention price
